Skip to main content

Table 2 Univariate and multivariable proportional hazards model for relapse-free and overall survival for SUCCESS serum samples

From: Methylation patterns in serum DNA for early identification of disseminated breast cancer

Characteristic Univariate analyses
Relapse-free survival   Overall survival  
HR (95% CI) P value HR (95% CI) P value
Menopausal status, post vs pre 1.323 (0.750–2.333) 0.335 2.872 (1.164–7.086) 0.022
Tumor size, T2-T4 vs T1 2.268 (1.187–4.332) 0.013 3.881 (1.343–11.218) 0.012
Lymph node involvement, N1-3 vs N0 1.645 (0.861–3.142) 0.132 3.012 (1.045–8.683) 0.041
Estrogen receptor (ER) status, ER- vs ER+ 1.316 (0.999–1.734) 0.051 1.333 (0.918–1.934) 0.131
Progesterone receptor (PR) status, PR- vs PR+ 1.180 (0.897–1.554) 0.237 1.219 (0.839–1.772) 0.298
HER2 status, HER2+ vs HER2- 1.907 (0.858–4.241) 0.113 1.789 (0.618–5.178) 0.283
Grading, G3 vs G1/2 1.079 (0.623–1.868) 0.786 1.129 (0.535–2.384) 0.75
CTCs before chemo, CTC+ vs CTC- 3.666 (2.110–6.368) <0.0001 5.681 (2.686–12.014) <0.0001
CTCs after chemo, CTC+ vs CTC- 1.401 (0.757–2.592) 0.283 1.467 (0.646–3.331) 0.36
EFC#93 before chemo, EFC#93+ vs EFC#93- 4.912 (2.613–9.233) <0.0001 7.689 (3.518–16.804) <0.0001
EFC#93 after chemo, EFC#93+ vs EFC#93- 1.913 (0.927–3.949) 0.079 1.807 (0.673–4.853) 0.24
  Multivariable analyses
Relapse-free survival   Overall survival  
HR (95% CI) P value HR (95% CI) P value
Menopausal status 1.294 (0.728–2.302) 0.379 2.688 (1.070–6.750) 0.035
Tumor size 1.763 (0.914–3.401) 0.091 2.945 (1.009–8.597) 0.048
Lymph node involvement 1.442 (0.750–2.775) 0.273 2.242 (0.765–6.566) 0.141
CTCs before chemo 2.847 (1.613–5.024) 0.0003 3.623 (1.681–7.812) 0.001
EFC#93 before chemo 3.782 (1.965–7.281) <0.0001 5.973 (2.634–13.542) <0.0001
  1. Cox proportional hazards models. All statistical tests were two-sided
  2. CI confidence interval, CTC circulating tumor cell, HR hazard ratio